Drug profile · INN
lutetium lu 177 dotatate
LUTATHERA
lutetium lu 177 dotatate (LUTATHERA) is a somatostatin receptor binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — lutetium lu 177 dotatate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lutetium lu 177 dotatate (LUTATHERA) is a somatostatin receptor binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Somatostatin receptor binding agent
Primary target: Somatostatin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lutetium lu 177 dotatate?
lutetium lu 177 dotatate (LUTATHERA) is a somatostatin receptor binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for lutetium lu 177 dotatate?
LUTATHERA is a marketed brand name for lutetium lu 177 dotatate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lutetium lu 177 dotatate?
lutetium lu 177 dotatate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.